Robert Lechleider
Known title: Chief Medical OfficerCIK: 0001997584
Robert Lechleider's purchase track record
Robert Lechleider has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/21/2024 | IMNM | $150K | +7.3% | -10.2% | -1.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IMNM | ▲ Buy | Grant | 54,000 | $0 | 7/23/2026 | View on chart |
| IMNM | ▲ Buy | Option Exercise | 55,000 | $480K | 7/2/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 22,714 | $499K | 7/2/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 16,214 | $369K | 7/2/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 16,072 | $377K | 7/2/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 40,580 | $794K | 6/25/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 14,420 | $298K | 6/25/2026 | View on chart |
| IMNM | ▲ Buy | Option Exercise | 55,000 | $480K | 6/25/2026 | View on chart |
| IMNM | ▲ Buy | Open Market | 15,805 | $150K | 11/21/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Immunome files Nasdaq inducement grant report, sees higher volume
Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.
Immunome files Nasdaq inducement grant report, sees higher volume. Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.